Navigation Links
Clue to genetic cause of fatal birth defect
Date:10/9/2008

omes dependent on the biosynthesis of its own cholesterol once this blood-brain barrier forms, at day 10 of gestation.

The UIC researchers established that in the fetus, the brain is the most important site for HSD17b7 expression and provided evidence that anencephaly may result from the loss of this enzyme.

"Creating a knockout mouse is a very laborious process," said Aurora Shehu, first author of the paper and at that time a graduate student in Gibori's laboratory. Mice with only one copy of the gene are produced and then interbred; one in four of their offspring should have no copy of the gene -- a "null" mouse.

"We expected null mice to be born and to be infertile, however, no null mice were born," said Shehu. "I was afraid I had made a mistake, and went back to the beginning, repeating the entire process, but still no null mice were born."

Shehu then began more painstaking work, performing in-utero genetic testing on entire litters -- often 10 to 12 fetuses per litter. She found that the null mice were there, but they were dying at day 10 of gestation, when the blood-brain barrier develops.

Gibori says the gene that is missing or defective in human anencephaly is not yet known, but the discovery that the deletion of HSD17b7 in the mouse causes anencephaly suggests this gene may be awry in the human disease.

"This opens up very exciting possibilities for understanding human anencephaly, and, perhaps, someday being able to provide a genetic test for the condition early in pregnancy -- and ultimately a therapy," she said.

As their next step, Gibori's lab plans to test human anencephalic tissue for a mutation in the HSD17b7 gene.


'/>"/>

Contact: Jeanne Galatzer-Levy
jgala@uic.edu
312-996-1583
University of Illinois at Chicago
Source:Eurekalert

Page: 1 2

Related biology news :

1. American College of Medical Genetics receives $13.5M NIH contract
2. Genetic finding implicates innate immune system in major cause of blindness
3. Study finds genetic variant plays role in cleft lip
4. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
5. Rare genetic disorder gives clues to autism, epilepsy, mental retardation
6. Childrens Hospital researchers identify genetic mutation that may predict organ rejection
7. K-State professors USDA research shows mad cow disease also caused by genetic mutation
8. How do race, genetics and health-care disparities affect spread of HIV?
9. Exploding chromosomes fuel research about evolution of genetic storage
10. Genetics reveals big fish that almost got away
11. Scientists discover major genetic cause of colorectal cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...xic dust: Toxins in coal-tar-based sealcoats in pa...e dust, according to a USGS study. PAHs or polyc...ound in oil, coal and tar deposits, and can have t...ften found in house dust; however, the specific so...archers found that dust from indoor areas near par...
(Date:11/20/2009)...November 19th 2009 - Bacteria possess an ingenious...building blocks of the cell. This is the new findi...sens of VIB, a life sciences research institute in...iteit Brussel. The scientists made this discovery ...Escherichia coli . By means of this model organism...
(Date:11/20/2009)...iomass from the production of flax shives, and gen... plant related to those which engulf fields in spr...een suggested by two studies carried out by Spanis...al Renewable and Sustainable Energy Reviews . , ...nt of view, the production of bioethanol from two,...
Breaking Biology News(10 mins):From toxic dust and algae to ill winds from Africa 2From toxic dust and algae to ill winds from Africa 3From toxic dust and algae to ill winds from Africa 4From toxic dust and algae to ill winds from Africa 5Biologists discover bacterial defense mechanism against aggressive oxygen 2Flax and yellow flowers can produce bioethanol 2Patrick Johnston Named President and CEO of the California Association of Health Plans 47986 1Patrick Johnston Named President and CEO of the California Association of Health Plans 47986 2XeoHealth 28R 29 Announces the Official US Launch of Its Flexible Real Time Adjudication Solutions at AHIP 2009 47983 1XeoHealth 28R 29 Announces the Official US Launch of Its Flexible Real Time Adjudication Solutions at AHIP 2009 47983 2XeoHealth 28R 29 Announces the Official US Launch of Its Flexible Real Time Adjudication Solutions at AHIP 2009 47983 3Prize4Life and the Alzheimer Research Forum Announce Launch of New Web Portal for ALS Research 47980 1Prize4Life and the Alzheimer Research Forum Announce Launch of New Web Portal for ALS Research 47980 2Prize4Life and the Alzheimer Research Forum Announce Launch of New Web Portal for ALS Research 47980 3
...rchers at the Saint Louis University Institute for...lecular mechanism by which the HIV virus infects, ...lead to new drug treatments for HIV. , Although sc... must come together inside a healthy cell in order...een able to illuminate the process. , "Many biolo...
...rints and march to the beat of subtly different ph... bioengineering researchers at the University of C...gorithms that identify the underlying sources of v...uctuations within individual cells and variations ...e that natural selection would prune any sloppines...
... diseases , A team of international researchers h...5 regulates inflammation, a finding with implicati...r, cardiovascular disease, diabetes, obesity, Alzh...ed in the October 9 online issue of Nature Genetic...of great interest to biomedical and pharmaceutical...
Other Biology News:SLU researchers uncover direct evidence on how HIV invades healthy cells 2Researchers quantify more noise in gene expression 2Researchers quantify more noise in gene expression 3Scientists pinpoint inflammation gene 2Scientists pinpoint inflammation gene 3Scientists pinpoint inflammation gene 4
(Date:11/19/2009)...EAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics In... in a randomized Phase 2B study of AEG35156, a tar...nt for multiple oncology indications. ,, The st...udy of the X-Linked Inhibitor of Apoptosis (XIAP) ...dose Cytarabine and Idarubicin in AML Following Fa...
(Date:11/19/2009)... World,s Top Gene Synthesis Companies For...o Coordinate Best Practices in Risk Reduction ,F...wide Gene Synthesis Capacity , ...ld’s leading gene synthesis companies today ...screening protocol to promote biosecurity in the g...
(Date:11/19/2009)... VIENNA, Austria, November 19 AF...m on one product candidate at an unexpectedly earl... is planned to enter into,Phase II clinical trial ...ately follows the completion of two Phase I trials...sed its fast decision on the first interim,analysi...
(Date:11/18/2009)...he National Institute of Standards and Technology ...ensive method for detecting and measuring elusive ...nvisible spoilage in food or pesticides distribute...s more sensitive than conventional techniques for ...arlike water molecules, having distinct electrical...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Prototype NIST method detects and measures elusive hazards 2
...ogramme With Oral Iclaprim, "Rolling" NDA for Intr...f First Modules due Before Year-en... Ltd,(SWX: ARPN) announced today the enrolment and...ical study with intravenous iclaprim in the treatm...tor-associated pneumonia,(VAP) / healthcare-associ...
... First Time on 50 mg/Day Dose for PRISTIQ for the ...rder, COLLEGEVILLE, Pa., Dec. 12 Wyeth,Pharmaceu...es that data from,two Phase 3 clinical studies of ...erotonin-norepinephrine reuptake inhibitor (SNRI),...ay dose of PRISTIQ for the,treatment of major depr...
...en Filed With the FDA for the Fourth Genmab Antibo...ion with Roche., COPENHAGEN, December 12 Genmab ...onal New Drug application (IND) for a,Genmab antib...th Roche has,been filed with the FDA by Roche. Gen...of the antibody which selectively blocks the inter...
Other Biology Technology:First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 3First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 4First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3
Mouse Anti-Human E1A (adenovirus early region 1) Monoclonal Antibody, Unconjugated, Clone M73 from Exalpha Biologicals, Inc.
Chicken Anti-Human Uridine Phosphorylase 1 Polyclonal Antibody, Unconjugated from Abcam
Chicken Anti-Nucleobindin 1 (NUCB1) Antibody, Unconjugated from CHEMICON
Anti-Presenilin-1, N-terminus Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: